Kymanox competitors

Zippia score 4.1

Kymanox main competitors are Genentech, Onyx Pharmaceuticals, and Amicus Therapeutics.

Competitor Summary. See how Kymanox compares to its main competitors:

Genentech has the most employees (13,638).
Employees at Genentech earn more than most of the competitors, with an average yearly salary of $97,473.
The oldest company is Genentech, founded in 1976.

Work at Kymanox?

Share your experience

Kymanox vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Kymanox	2004	4.1	Durham, NC	1	$13.0M	185
ComplianceCrossing	2007	4.1	Ephraim, UT	1	$47.0M	750
Amicus Therapeutics	2002	4.6	Cranbury, NJ	2	$528.3M	508
Onyx Pharmaceuticals	1992	4.8	South San Francisco, CA	2	$362.2M	500
BioMarin	1997	4.6	San Rafael, CA	4	$2.9B	2,581
PDL BioPharma	1986	4.2	Incline Village, NV	1	$30.7M	75
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123
Genentech	1976	4.5	South San Francisco, CA	5	$166.9M	13,638

Rate how well Kymanox differentiates itself from its competitors.

Kymanox salaries vs competitors

Among Kymanox competitors, employees at Genentech earn the most with an average yearly salary of $97,473.

Compare Kymanox salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Kymanox	$87,210	$41.93	-
ComplianceCrossing	$84,127	$40.45	-
Amicus Therapeutics	$88,124	$42.37	-
Onyx Pharmaceuticals	$95,378	$45.85	-
BioMarin	$87,259	$41.95	-
PDL BioPharma	$48,962	$23.54	-

Compare Kymanox job title salaries vs competitors

Company	Highest salary	Hourly salary
Kymanox	$139,127	$66.89
Genentech	$173,283	$83.31
Regeneron	$149,503	$71.88
Onyx Pharmaceuticals	$148,593	$71.44
Amicus Therapeutics	$146,155	$70.27
BioMarin	$142,800	$68.65
PDL BioPharma	$139,701	$67.16
ComplianceCrossing	$122,129	$58.72

Do you work at Kymanox?

Does Kymanox effectively differentiate itself from competitors?

Kymanox jobs

Kymanox demographics vs competitors

Compare gender at Kymanox vs competitors

Job title	Male	Female
Amicus Therapeutics	43%	57%
PDL BioPharma	46%	54%
BioMarin	50%	50%
Regeneron	54%	46%
Genentech	54%	46%
Kymanox	-	-

Male

Female

100%

75%

50%

25%

Kymanox

25%

50%

75%

100%

Compare race at Kymanox vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Amicus Therapeutics	47%	17%	9%	21%	6%	8.8
BioMarin	43%	20%	8%	23%	7%	9.6
PDL BioPharma	54%	15%	7%	19%	4%	9.3
Regeneron	54%	15%	10%	17%	4%	9.8
Genentech	45%	20%	7%	22%	6%	9.8

Kymanox and similar companies CEOs

CEOBio

John Francis Crowley

Amicus Therapeutics

John Francis Crowley (born April 7, 1967) is an American biotechnology executive and entrepreneur and the chairman and CEO of Amicus Therapeutics. He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, and founded Orexigen Therapeutics. In 2006, he was profiled in the book The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children by Geeta Anand. In 2010, Crowley released his memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy. Crowley and his family were the inspiration for the movie Extraordinary Measures starring Harrison Ford and Brendan Fraser in 2010.

Jean Jacques Bienaime

BioMarin

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Christopher Stone

PDL BioPharma

Alexander Hardy

Genentech

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.